YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Results of Extraordinary General Meeting
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
YS Biopharma Announces Appointment of New Directors
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
YS Biopharma Announces US$40 Million Private Placement Financing
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
YS Biopharma Announces Changes to its Board Committees
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023
3 Penny Stocks That Are Too Compelling to Ignore
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
YS Biopharma Announces Receipt of Nasdaq Notice
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference
Why Is YS Biopharma (YS) Stock Up 71% Today?
Why Is YS Biopharma (YS) Stock Up 71% Today?
YS Biopharma Announces Purchase of Shares by Company Officers
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023
Why Is YS Biopharma (YS) Stock Up 31% Today?
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)